In The News

Life Sciences Co-Chair Quoted on FDA Targeting More Genetic Testing Firms

Practices: Life Sciences

Bloomberg BNA’s Medical Devices Law & Industry Report quotes life sciences partner Gregory Levine (Washington, D.C.) in a Dec. 10 article that examines the FDA’s increased monitoring of companies marketing direct-to-consumer drug metabolism genetic tests. Mr. Levine explains that the effect of the letters to genetic test makers is to inform them that they may be marketing an illegal product, but the FDA is not using a warning letter at this stage. 
Cookie Settings